A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients

N. C T Kong, J. Beran, S. A. Kee, J. L. Miguel, C. Sánchez, J. M. Bayas, A. Vilella, F. Calbo-Torrecillas, E. López De Novales, K. Srinivasa, M. Stoffel, B. Hoet

    Research output: Contribution to journalArticle

    59 Citations (Scopus)

    Abstract

    Prehemodialysis and hemodialysis patients are at an increased risk of hepatitis B infection and have an impaired immune response to hepatitis B vaccines. We evaluated the immune response to the new adjuvant of hepatitis B vaccine AS04 (HBV-AS04) in this population. We measured antibody persistence for up to 42 months, and the anamnestic response and safety of booster doses in patients who were no longer seroprotected. The primary vaccination study showed that HBV-AS04 elicited an earlier antibody response and higher antibody titers than four double doses of standard hepatitis B vaccine. Seroprotection rates were significantly higher in HBV-AS04 recipients throughout the study. The decline in seroprotection over time was significantly less in the HBV-AS04 group with significantly fewer primed patients requiring a booster dose over the follow-up period. Solicited/unsolicited adverse events were rare following booster administration. Fifty-seven patients experienced a serious adverse event during the follow-up; none of which was vaccine related. When HBV-AS04 was used as the priming immunogen, the need for a booster dose occurred at a longer time compared to double doses of standard hepatitis B vaccine. Hence, in this population, the HBV-AS04 was immunogenic, safe, and well-tolerated both as a booster dose after HBV-AS04 or standard hepatitis B vaccine priming.

    Original languageEnglish
    Pages (from-to)856-862
    Number of pages7
    JournalKidney International
    Volume73
    Issue number7
    DOIs
    Publication statusPublished - Apr 2008

    Fingerprint

    Hepatitis B Vaccines
    Renal Dialysis
    Antibodies
    hepatitis B vaccine AS04
    Hepatitis B
    Population
    Antibody Formation
    Vaccination
    Vaccines
    Safety
    Infection

    Keywords

    • Adjuvant
    • Booster
    • FENDrix vaccine
    • Hemodialysis
    • Hepatitis B
    • Seroprotection

    ASJC Scopus subject areas

    • Nephrology

    Cite this

    Kong, N. C. T., Beran, J., Kee, S. A., Miguel, J. L., Sánchez, C., Bayas, J. M., ... Hoet, B. (2008). A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney International, 73(7), 856-862. https://doi.org/10.1038/sj.ki.5002725

    A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. / Kong, N. C T; Beran, J.; Kee, S. A.; Miguel, J. L.; Sánchez, C.; Bayas, J. M.; Vilella, A.; Calbo-Torrecillas, F.; López De Novales, E.; Srinivasa, K.; Stoffel, M.; Hoet, B.

    In: Kidney International, Vol. 73, No. 7, 04.2008, p. 856-862.

    Research output: Contribution to journalArticle

    Kong, NCT, Beran, J, Kee, SA, Miguel, JL, Sánchez, C, Bayas, JM, Vilella, A, Calbo-Torrecillas, F, López De Novales, E, Srinivasa, K, Stoffel, M & Hoet, B 2008, 'A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients', Kidney International, vol. 73, no. 7, pp. 856-862. https://doi.org/10.1038/sj.ki.5002725
    Kong, N. C T ; Beran, J. ; Kee, S. A. ; Miguel, J. L. ; Sánchez, C. ; Bayas, J. M. ; Vilella, A. ; Calbo-Torrecillas, F. ; López De Novales, E. ; Srinivasa, K. ; Stoffel, M. ; Hoet, B. / A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. In: Kidney International. 2008 ; Vol. 73, No. 7. pp. 856-862.
    @article{994f168993ed400387c333a7aca19380,
    title = "A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients",
    abstract = "Prehemodialysis and hemodialysis patients are at an increased risk of hepatitis B infection and have an impaired immune response to hepatitis B vaccines. We evaluated the immune response to the new adjuvant of hepatitis B vaccine AS04 (HBV-AS04) in this population. We measured antibody persistence for up to 42 months, and the anamnestic response and safety of booster doses in patients who were no longer seroprotected. The primary vaccination study showed that HBV-AS04 elicited an earlier antibody response and higher antibody titers than four double doses of standard hepatitis B vaccine. Seroprotection rates were significantly higher in HBV-AS04 recipients throughout the study. The decline in seroprotection over time was significantly less in the HBV-AS04 group with significantly fewer primed patients requiring a booster dose over the follow-up period. Solicited/unsolicited adverse events were rare following booster administration. Fifty-seven patients experienced a serious adverse event during the follow-up; none of which was vaccine related. When HBV-AS04 was used as the priming immunogen, the need for a booster dose occurred at a longer time compared to double doses of standard hepatitis B vaccine. Hence, in this population, the HBV-AS04 was immunogenic, safe, and well-tolerated both as a booster dose after HBV-AS04 or standard hepatitis B vaccine priming.",
    keywords = "Adjuvant, Booster, FENDrix vaccine, Hemodialysis, Hepatitis B, Seroprotection",
    author = "Kong, {N. C T} and J. Beran and Kee, {S. A.} and Miguel, {J. L.} and C. S{\'a}nchez and Bayas, {J. M.} and A. Vilella and F. Calbo-Torrecillas and {L{\'o}pez De Novales}, E. and K. Srinivasa and M. Stoffel and B. Hoet",
    year = "2008",
    month = "4",
    doi = "10.1038/sj.ki.5002725",
    language = "English",
    volume = "73",
    pages = "856--862",
    journal = "Kidney International",
    issn = "0085-2538",
    publisher = "Nature Publishing Group",
    number = "7",

    }

    TY - JOUR

    T1 - A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients

    AU - Kong, N. C T

    AU - Beran, J.

    AU - Kee, S. A.

    AU - Miguel, J. L.

    AU - Sánchez, C.

    AU - Bayas, J. M.

    AU - Vilella, A.

    AU - Calbo-Torrecillas, F.

    AU - López De Novales, E.

    AU - Srinivasa, K.

    AU - Stoffel, M.

    AU - Hoet, B.

    PY - 2008/4

    Y1 - 2008/4

    N2 - Prehemodialysis and hemodialysis patients are at an increased risk of hepatitis B infection and have an impaired immune response to hepatitis B vaccines. We evaluated the immune response to the new adjuvant of hepatitis B vaccine AS04 (HBV-AS04) in this population. We measured antibody persistence for up to 42 months, and the anamnestic response and safety of booster doses in patients who were no longer seroprotected. The primary vaccination study showed that HBV-AS04 elicited an earlier antibody response and higher antibody titers than four double doses of standard hepatitis B vaccine. Seroprotection rates were significantly higher in HBV-AS04 recipients throughout the study. The decline in seroprotection over time was significantly less in the HBV-AS04 group with significantly fewer primed patients requiring a booster dose over the follow-up period. Solicited/unsolicited adverse events were rare following booster administration. Fifty-seven patients experienced a serious adverse event during the follow-up; none of which was vaccine related. When HBV-AS04 was used as the priming immunogen, the need for a booster dose occurred at a longer time compared to double doses of standard hepatitis B vaccine. Hence, in this population, the HBV-AS04 was immunogenic, safe, and well-tolerated both as a booster dose after HBV-AS04 or standard hepatitis B vaccine priming.

    AB - Prehemodialysis and hemodialysis patients are at an increased risk of hepatitis B infection and have an impaired immune response to hepatitis B vaccines. We evaluated the immune response to the new adjuvant of hepatitis B vaccine AS04 (HBV-AS04) in this population. We measured antibody persistence for up to 42 months, and the anamnestic response and safety of booster doses in patients who were no longer seroprotected. The primary vaccination study showed that HBV-AS04 elicited an earlier antibody response and higher antibody titers than four double doses of standard hepatitis B vaccine. Seroprotection rates were significantly higher in HBV-AS04 recipients throughout the study. The decline in seroprotection over time was significantly less in the HBV-AS04 group with significantly fewer primed patients requiring a booster dose over the follow-up period. Solicited/unsolicited adverse events were rare following booster administration. Fifty-seven patients experienced a serious adverse event during the follow-up; none of which was vaccine related. When HBV-AS04 was used as the priming immunogen, the need for a booster dose occurred at a longer time compared to double doses of standard hepatitis B vaccine. Hence, in this population, the HBV-AS04 was immunogenic, safe, and well-tolerated both as a booster dose after HBV-AS04 or standard hepatitis B vaccine priming.

    KW - Adjuvant

    KW - Booster

    KW - FENDrix vaccine

    KW - Hemodialysis

    KW - Hepatitis B

    KW - Seroprotection

    UR - http://www.scopus.com/inward/record.url?scp=40849130233&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=40849130233&partnerID=8YFLogxK

    U2 - 10.1038/sj.ki.5002725

    DO - 10.1038/sj.ki.5002725

    M3 - Article

    VL - 73

    SP - 856

    EP - 862

    JO - Kidney International

    JF - Kidney International

    SN - 0085-2538

    IS - 7

    ER -